Novartis has joined Shinsei Corporate Investment, Seventure Partners, INCJ and Mitsubishi UFJ Capital in a $13.2m round for the cancer drug developer.
Japan-based oncology drug developer Anaeropharma Science received $13.2m in funding yesterday from investors including pharmaceutical firm Novartis and Shinsei Corporate Investment, a subsidiary of financial services firm Shinsei Bank.
Venture capital firm Seventure Partners also took part in the round, through its Health for Life Capital fund, as did the state-backed Innovation Network Corporation of Japan (INCJ) and a fund managed by Mitsubishi UFJ Capital, the VC arm of Mitsubishi UFJ Financial Group.
Anaeropharma is researching and developing cancer drugs…
